Emami Reports Q4FY26 Results; Core Domestic Portfolio Remains Resilient Amid External Headwinds

EBITDA margin compressionExceptional itemRelated-party transactionsResults View source PDF Explain this filing

EMAMILTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.1%Reaction day

₹427.05

prior close

₹412.95

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.7%-3.8% vs market

Personal Care peers, median of 13sector-0.4%-2.7% vs sector

On the reaction day the stock moved 3.8 pts less than Nifty Smallcap 250 and 2.7 pts less than its Personal Care peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.4

15m

+0.5

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.1+0.7-3.8-0.4-2.7

Next day

-5.7+0.6-6.3+0.2-5.9

-5.3+1.8-7.1+0.6-5.9

-5.2+2.0-7.2+1.4-6.6

-6.2+2.6-8.8+2.1-8.3

-6.5+1.9-8.4+0.3-6.8

-8.3+1.6-9.9-2.5-5.7

15d

-8.5+2.4-10.9-4.4-4.1

-4.8+7.0-11.8-5.1+0.4

-6.1+8.5-14.6-4.5-1.6

-5.7+10.4-16.2-9.0+3.2

UpDownMarket · Nifty Smallcap 250Sector · Personal Care peers, median of 13Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Emami reported Q4FY26 consolidated revenues of ₹925 crore, down 4% YoY, impacted by a disrupted summer season and geopolitical disruptions in West Asia affecting its international business. Gross margins expanded 250 bps to 68.4% due to cost discipline and pricing actions. EBITDA fell 15% to ₹187 crore while PAT declined ~12% to ₹143 crore. For the full year FY26, revenues stood at ₹3,780 crore with EBITDA at ₹964 crore and PAT at ₹775 crore. Despite the topline decline, the non-summer domestic portfolio delivered healthy 11% growth, and organised channels now contribute ~32% of domestic business. The company made two strategic investments — increasing stake in Axiom Ayurveda (making it a subsidiary) and acquiring majority stake in IncNut (Vedix, SkinKraft) — to expand into health beverages and personalised BPC. The balance sheet remains debt-free with net cash of ₹883 crore. Dividend of ₹10 per share was declared, representing a 51% payout.

Likely market impact

Near-term pressure from seasonal and geopolitical headwinds is evident in the revenue and EBITDA decline, but margin expansion and strategic acquisitions signal long-term growth positioning. The company's debt-free status and strong cash position provide resilience for future investments.